By PR Newswire, October 25, 2013, 08:00:00 AM EDT
NEW YORK, October 25, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Zoetis Inc. (NYSE:ZTS), United Therapeutics Corporation (NASDAQ:UTHR), BioReference Laboratories Inc. (NASDAQ:BRLI), ICON Public Limited Company (NASDAQ:ICLR), and Abaxis, Inc. (NASDAQ:ABAX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Zoetis Inc. Research Report
On October 22, 2013, Zoetis Inc. (Zoetis) announced that it is supporting the "Animal Connections: Our Journey Together" exhibition on wheels. Zoetis reported that "Animal Connections" is a custom-built exhibition housed on an 18-wheel truck that expands into 1,000 square feet of space, which offers free admission from 10:00 a.m. to 4:00 p.m., however, pets are not allowed inside the truck. According to Zoetis, the exhibition will be on view on the National Mall between the Smithsonian Castle and the Smithsonian's National Museum of Natural History beginning Saturday, October 26, 2013 through Monday, October 28, 2013 before moving near the US Botanic Garden on Tuesday, October 29, 2013. Clint Lewis, Executive Vice President and President of US business at Zoetis, stated, "As part of our commitment to veterinarians, we are proud to join with the Smithsonian and the AVMA in supporting 'Animal Connections' as a means to inspire young people to pursue careers in veterinary medicine and its allied professions." The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/7e25_ZTS]
United Therapeutics Corporation Research Report
On October 22, 2013, United Therapeutics Corporation (United Therapeutics) announced that it will release its Q3 2013 results before the market opens on Tuesday, October 29, 2013. United Therapeutics reported that the release will be followed by its Q3 2013 conference call on the same day, at 9:00 a.m. ET. The Company informed that interested parties may access the webcast through its Investor Relations website or listen to the live call through the designated dial-in lines. The Full Research Report on United Therapeutics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e4cc_UTHR]
BioReference Laboratories Inc. Research Report
On October 22, 2013, BioReference Laboratories Inc. (BioReference) announced that Myriad Genetics has filed a lawsuit against it in the Federal District Court in Utah alleging that BioReference, through its genetic sequencing laboratory, GeneDx, Inc., is infringing on its intellectual property by offering OncoGeneDx, its comprehensive series of inherited cancers testing, including testing for BRCA1/2. BioReference further indicated that it is not surprised by the action and that it is confident in its position. According to the Company, it is fully prepared to face Myriad Genetics in court with the help of Sterne, Kessler, Goldstein & Fox. The Full Research Report on BioReference Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/1f59_BRLI]
ICON Public Limited Company Research Report
On October 9, 2013, ICON Public Limited Company (ICON) launched ICONIK Patient Safety, the latest service to leverage its ICONIK technology platform. ICON reported that ICONIK Patient Safety offers a systematic way to monitor safety trends in accumulating data, spot potential safety issues and take appropriate corrective and preventative action while the study is on-going. Dr. Peter Schueler, Senior Vice President Medical and Safety Services, ICON Clinical Research, said, "Patient wellbeing is paramount in any clinical trial. ICONIK Patient Safety allows real-time review of integrated patient safety data, thereby improving our ability to identify and monitor unexpected adverse events. ICONIK Patient Safety helps study teams maintain a view of a drug's evolving safety profile by accumulating safety data in real-time and allowing for quick identification of emerging safety issues, affording greater protection of patients' well-being. Before ICONIK Patient Safety, this level of dynamic analysis and management of patient safety was simply not possible." The Full Research Report on ICON Public Limited Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/fbb0_ICLR]
Abaxis, Inc. Research Report
On October 22, 2013, Abaxis, Inc. (Abaxis) released its Q2 FY 2014 results (period ended September 30, 2013). Abaxis registered revenues of $45.9 million, up 3.6% YoY in Q2 FY 2014. The Company's net income was $4.0 million in Q2 FY 2014, compared to net income of $12.9 million in Q2 FY 2013. Abaxis posted diluted EPS of $0.18 for Q2 FY 2014, compared to diluted EPS of $0.58 in Q2 FY 2013. The Full Research Report on Abaxis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ec55_ABAX]
This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner